目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T4327 | Apoptosis Chk S6 Kinase | ||
Prexasertib dihydrochloride (LY2606368) 是一种选择性的,ATP 竞争性的细胞周期检测点激酶 1 抑制剂,Ki 为 0.9 nM,IC50为 <1 nM。它抑制 CHK2(IC50=8 nM) 和 RSK1 (IC50=9 nM)。它引起双链 DNA 断裂和复制突变,导致细胞凋亡,有抗肿瘤活性。 | |||
TN2019 | BCL Caspase PI3K | ||
Orobol (3’,4’,5,7-tetrahydroxy-isoflavon) 是酪氨酸特异性蛋白激酶和磷脂酰肌醇转换的抑制剂。Orobol 抑制 PI3K,对 PI3K α/β/γ/K/δ 的 IC50 为 3.46-5.27 μM。 Orobol 具有抗皮肤老化和抗肥胖的作用。 | |||
T8825 | c-Met/HGFR | ||
Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) 是一种具有潜在抗肿瘤活性的原癌基因 c-Met (HGFR) 的口服生物可利用抑制剂。 | |||
T4230 | Apoptosis PAK | ||
PF-3758309 hydrochloride (PF-03758309 hydrochloride) 是一种口服的、可逆的 ATP 竞争性PAK4抑制剂,Kd 为 2.7 nM,Ki 为 18.7 nM。它抑制锚定独立生长、诱导凋亡、细胞骨架重塑和抑制增殖,具有 PAK4 抑制剂的预期细胞功能。 | |||
T8840 | Apoptosis S1P Receptor Autophagy LPL Receptor | ||
PF-543 hydrochloride (PF-543) 是一种选择性可逆和鞘氨醇竞争性SPHK1抑制剂,对SPHK1的选择性是 SPHK2 的 100 倍以上。它还是全血中 1-磷酸鞘氨醇形成的有效抑制剂,诱导细胞凋亡、坏死和自噬。 | |||
T21254 | Proton pump | ||
Vonoprazan Fumarate (TAK438) 是质子泵的有效抑制剂,是口服有效的高效钾竞争性酸阻断剂,具有抗分泌活性。在 pH 为 6.5 时,它抑制猪胃微粒体中的 H+,K+-ATPase 酶活性,IC50为 19 nM。它被开发用于研究酸相关疾病,如消化性溃疡和胃食管反流病。 | |||
T10898 | Apoptosis CDK | ||
Samuraciclib hydrochloride (ICEC0942 hydrochloride) 是一种具有选择性,ATP 竞争性和口服活性的CDK7抑制剂,IC50为 41 nM。它以 GI50值为 0.2-0.3 µM 来抑制乳腺癌细胞系的生长,具有抗肿瘤作用。 | |||
T23127 | EGFR FGFR PDGFR Src | ||
PD-161570 是一种有效的 ATP 竞争性人 FGF-1 受体抑制剂,IC50 为 39.9 nM,Ki 为 42 nM。它还是骨形态发生蛋白 (BMPs) 和TGF-β信号抑制剂。它抑制PDGF 刺激的自磷酸化和FGF-1受体磷酸化,IC50分别为 450 和 622 nM。它抑制 PDGFR、EGFR 和 c-Src 酪氨酸激酶,IC50 值分别为 310、240 和 44 nM。 | |||
T2253 | Pim | ||
TCS PIM-1 1 (SC 204330) 是一种特异性有效的 ATP 竞争性 Pim-1 激酶抑制剂,IC50为 50 nM,对 MEK1/MEK2 和 Pim-2 表现出良好的特异性,IC50值大于 20000 nM。 | |||
T8416 | c-Met/HGFR | ||
Capmatinib xHCl (INCB28060) 是一种有效的、口服活性的、选择性的和 ATP 竞争性 c-Met 激酶抑制剂,有效地阻断体外激酶活性 (IC50 = 0.13 nM) 以及在细胞中的组成型或 HGF 刺激活性(IC50 值范围从 0.3 到1.1纳米)。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPJ-00473 | QPRTase Protein, Human, Recombinant (His) | Human | E. coli | ||
Nicotinate-Nucleotide Pyrophosphorylase (QPRT) belongs to the nadC/modD family. QPRT plays an improtant role in catabolism of quinolinate which acts as a potent endogenous exitotoxin to neurons. In addition, QPRT serves as an an intermediate in the Tryptophan-Nicotinamide Adenine Dinucleotide pathway. QPRT participates in some pathways including Cofactor biosynthesis, NAD(+) biosynthesis and the Nicotinate D-Ribonucleotide from Quinolinate. In addition, QPRT is involved in the catabolism of Quinolinic Acid (QA). The activity toward QA is slightly repressed by phosphoribosylpyrophosphate (PRPP) in both a competitive and a non-competitive manner.
|
|||||
TMPH-00893 | AHCY Protein, Human, Recombinant (His & SUMO) | Human | E. coli | ||
Adenosylhomocysteine is a competitive inhibitor of S-adenosyl-L-methionine-dependent methyl transferase reactions; therefore adenosylhomocysteinase may play a key role in the control of methylations via regulation of the intracellular concentration of adenosylhomocysteine. AHCY Protein, Human, Recombinant (His & SUMO) is expressed in E. coli expression system with N-6xHis-SUMO tag. The predicted molecular weight is 63.6 kDa and the accession number is P23526.
|
|||||
TMPK-00839 | ITGB6 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
ITGB6 is known to be one of the major receptor components involved in host tropism of foot-and-mouth disease (FMD) virus in cattle. A competitive PCR technique called ARMS PCR was adapted to identify a single-nucleotide polymorphism (SNP), G29A, db SNP Id: rs109075046, in the 5' untranslated region (5'UTR) of the bovine ITGB6 gene. ITGB6 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 75.4 kDa and the accession number is P18564-1.
|
|||||
TMPK-01247 | ITGB6 Protein, Mouse, Recombinant (His) | Mouse | HEK293 Cells | ||
ITGB6 is known to be one of the major receptor components involved in host tropism of foot-and-mouth disease (FMD) virus in cattle. A competitive PCR technique called ARMS PCR was adapted to identify a single-nucleotide polymorphism (SNP), G29A, db SNP Id: rs109075046, in the 5' untranslated region (5'UTR) of the bovine ITGB6 gene. ITGB6 Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 75.7 kDa and the accession number is Q9Z0T9.
|
|||||
TMPH-00227 | Beta-casein Protein, Bovine, Recombinant (His & Myc) | Bovine | E. coli | ||
Important role in determination of the surface properties of the casein micelles.; Casoparan acts as a macrophage activator, increasing the phagocytic activity of macrophages and peroxide release from macrophages. It also acts as a bradykinin-potentiating peptide.; Casohypotensin acts as a bradykinin-potentiating peptide. Induces hypotension in rats. Acts as a strong competitive inhibitor of endo-oligopeptidase A.; Antioxidant peptide has antioxidant activity. Beta-casein Protein, Bovine, Recombinant (His & Myc) is expressed in E. coli expression system with N-10xHis and C-Myc tag. The predicted molecular weight is 28.6 kDa and the accession number is P02666.
|
|||||
TMPH-02941 | MAFK Protein, Mouse, Recombinant (His & Myc & SUMO) | Mouse | E. coli | ||
Since they lack a putative transactivation domain, the small Mafs behave as transcriptional repressors when they dimerize among themselves. However, they act as transcriptional activators by dimerizing with other (usually larger) basic-zipper proteins, such as NFE2, NFE2L1/NRF1, NFE2L2/NRF2 and NFE2L3/NRF3, and recruiting them to specific DNA-binding sites. Small Maf proteins heterodimerize with Fos and may act as competitive repressors of the NF-E2 transcription factor. MAFK Protein, Mouse, Recombinant (His & Myc & SUMO) is expressed in E. coli expression system with N-10xHis-SUMO and C-Myc tag. The predicted molecular weight is 37.5 kDa and the accession number is Q61827.
|
|||||
TMPH-02940 | MAFK Protein, Mouse, Recombinant (His & Myc) | Mouse | HEK293 Cells | ||
Since they lack a putative transactivation domain, the small Mafs behave as transcriptional repressors when they dimerize among themselves. However, they act as transcriptional activators by dimerizing with other (usually larger) basic-zipper proteins, such as NFE2, NFE2L1/NRF1, NFE2L2/NRF2 and NFE2L3/NRF3, and recruiting them to specific DNA-binding sites. Small Maf proteins heterodimerize with Fos and may act as competitive repressors of the NF-E2 transcription factor. MAFK Protein, Mouse, Recombinant (His & Myc) is expressed in HEK293 mammalian cells with N-10xHis and C-Myc tag. The predicted molecular weight is 21.5 kDa and the accession number is Q61827.
|
|||||
TMPJ-01309 | PKI-Beta Protein, Human, Recombinant (His) | Human | E. coli | ||
cAMP-Dependent Protein Kinase Inhibitor β (PKI-β) is a member of the PKI family. As a member of the cAMP-dependent protein kinase inhibitor family,It has been shown that PKI-β is an extremely potent competitive inhibitor of cAMP-dependent protein kinase activity; this protein interacts with the catalytic subunit of the enzyme after the cAMP-induced dissociation of its regulatory chains. It may play a role in the protein kinase A (PKA) pathway by interacting with the catalytic subunit of PKA, and overexpression of this gene may play a role in prostate cancer.
|
|||||
TMPY-01769 | 4EBP1 Protein, Human, Recombinant (His) | Human | E. coli | ||
The translational suppressor eIF4E binding protein-1, 4E-BP1 functions as a key regulator in cellular growth, differentiation, apoptosis and survival. The Eif4ebp1 gene, encoding 4E-BP1, is a direct target of a transcription factor activating transcription factor-4 (ATF4), a master regulator of gene expression in stress responses. 4E-BP1 is characterized by its capacity to bind specifically to eIF4E and inhibit its interaction with eIF4G. Phosphorylation of 4E-BP1 regulates eIF4E availability, and therefore, cap-dependent translation, in cell stress. Binding of eIF4E to eIF4G is inhibited in a competitive manner by 4E-BP1. Phosphorylation of 4E-BP1 decreases the affinity of this protein for eIF4E, thus favouring the binding of eIF4G and enhancing translation. 4E-BP1 is important for beta-cell survival under endoplasmic reticulum (ER) stress. 4E-BP1 mediates the regulation of protein translation by hormones, growth factors and other stimuli that signal through the MAP kinase and mTORC1 pathways. Recently, 4E-BP1 was found to be a key factor, which converges several oncogenic signals, phosphorylates the molecules, and drives the downstream proliferative signals. Recent studies showed that high expression of phosphorylated 4E-BP-1 (p-4E-BP1) is associated with poor prognosis, tumor progression, or nodal metastasis in different human cancers.
|